Literature DB >> 176331

Glioblastoma multiforme in children.

G J Dohrmann, J R Farwell, J T Flannery.   

Abstract

Of 488 children with central nervous system neoplasms, 43 (8.8%) had glioblastomas, 22 of which were in the cerebral hemispheres, 16 in the brain stem, two in the cerebellum, and three in the spinal cord. The male to female ratio was 3:2. Glioblastoma multiforme of the cerebral hemispheres occurred at a mean age of 12.7 years, and the frontal lobe was the most commonly involved. Main presenting symptoms included headache (85%), nausea or vomiting (65%), and seizures (35%). Papilledema (45%) was the most common physical finding. The longest survivals were achieved by a combination of operation and radiation (22 months). Brain stem glioblastomas occurred at a mean age of 6.7 years, with the pons as the most frequent site. Nausea or vomiting (50%) and headache (36%) were the main presenting symptoms; the major physical findings were ataxia (43%), cranial nerve palsies (28%), and paresis (28%). The length of survival was greatest with radiation alone (10.5 months). The period of survival of children with glioblastoma multiforme was significantly increased with steroid therapy. Glioblastoma multiforme behaves similarly in children and adults. Intracranial glioblastomas have a more rapidly fatal course than that of other similarly situated gliomas in childhood.

Entities:  

Mesh:

Year:  1976        PMID: 176331     DOI: 10.3171/jns.1976.44.4.0442

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  37 in total

1.  Long-term survival in a patient with supratentorial glioblastoma: clinical considerations.

Authors:  L Cervoni; P Celli; M Salvati
Journal:  Ital J Neurol Sci       Date:  1998-08

Review 2.  Glioblastoma multiforme: morphology and biology.

Authors:  K Jellinger
Journal:  Acta Neurochir (Wien)       Date:  1978       Impact factor: 2.216

3.  N-myc oncogene amplification in a pediatric case of glioblastoma multiforme.

Authors:  A M Stenger; M L Garrè; A Cama; L Andreussi; M Brisigotti; G P Tonini; P Cornaglia-Ferraris
Journal:  Childs Nerv Syst       Date:  1991-11       Impact factor: 1.475

Review 4.  Primary malignant astrocytoma of the cerebellum in children. Report of a case with electron microscopic and cytofluorometric DNA evaluation.

Authors:  Y Itoh; M Kowada; K Mineura; H Kojima; M Sageshima
Journal:  Childs Nerv Syst       Date:  1988-10       Impact factor: 1.475

5.  Glioblastoma multiforme: Molecular characterization and current treatment strategy (Review).

Authors:  Xiang Zhang; Wei Zhang; Wei-Dong Cao; Gang Cheng; Yong-Qiang Zhang
Journal:  Exp Ther Med       Date:  2011-10-18       Impact factor: 2.447

6.  Craniocerebral epidermoids and dermoids. A review of 44 cases.

Authors:  G Rubin; R Scienza; A Pasqualin; L Rosta; R Da Pian
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

7.  Malignant monstrocellular brain tumours. A study of 42 surgically treated cases.

Authors:  L Palma; P Celli; A Maleci; N Di Lorenzo; G Cantore
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

8.  Glioblastoma multiforme in children: experience at Hospital Infantil de Mexico Federico Gomez.

Authors:  Federico Sánchez-Herrera; Eduardo Castro-Sierra; Luis Felipe Gordillo-Domínguez; Miguel Angel Vaca-Ruiz; Blanca Santana-Montero; Mario Perezpeña-Diazconti; Vicente González-Carranza; Samuel Torres-García; Fernando Chico-Ponce de León
Journal:  Childs Nerv Syst       Date:  2009-01-16       Impact factor: 1.475

9.  Glioblastoma of the cerebellum in children and adolescents. Case report and review of the literature.

Authors:  P M Georges; J Noterman; J Flament-Durand
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

10.  Malignant hemispheric tumors in childhood.

Authors:  E Hoppe-Hirsch; J F Hirsch; A Lellouch-Tubiana; A Pierre-Kahn; C Sainte-Rose; D Renier
Journal:  Childs Nerv Syst       Date:  1993-06       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.